1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Delayed Hypersensitivity in 1 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM." | 1.40 | Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat ( Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 1 |
| Balan, G | 1 |
| Barreiro, G | 1 |
| Boscoe, BP | 1 |
| Chenard, LK | 1 |
| Cianfrogna, J | 1 |
| Claffey, MM | 1 |
| Chen, L | 1 |
| Coffman, KJ | 1 |
| Drozda, SE | 1 |
| Dunetz, JR | 1 |
| Fonseca, KR | 1 |
| Galatsis, P | 1 |
| Grimwood, S | 1 |
| Lazzaro, JT | 1 |
| Mancuso, JY | 1 |
| Miller, EL | 1 |
| Reese, MR | 1 |
| Rogers, BN | 1 |
| Sakurada, I | 1 |
| Skaddan, M | 1 |
| Smith, DL | 1 |
| Stepan, AF | 1 |
| Trapa, P | 1 |
| Tuttle, JB | 1 |
| Verhoest, PR | 1 |
| Walker, DP | 1 |
| Wright, AS | 1 |
| Zaleska, MM | 1 |
| Zasadny, K | 1 |
| Shaffer, CL | 1 |
1 other study available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Delayed Hypersensitivity
| Article | Year |
|---|---|
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; | 2014 |